|
Business Combinations (Narrative) (Details) (USD $)
|
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 0 Months Ended | 3 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 25, 2011
|
Jun. 25, 2011
|
Dec. 25, 2010
Sentinelle Medical [Member]
Minimum [Member]
|
Jun. 25, 2011
TCT International Co [Member]
Maximum [Member]
|
Dec. 25, 2010
Sentinelle Medical [Member]
Maximum [Member]
|
Jul. 19, 2011
Maximum [Member]
Beijing Healthcome Technology [Member]
|
Jun. 25, 2011
Interlace Medical, Inc [Member]
Developed Technology [Member]
|
Jun. 25, 2011
Sentinelle Medical [Member]
Developed Technology [Member]
|
Jun. 25, 2011
TCT International Co [Member]
Customer Relationships [Member]
|
Jun. 25, 2011
Sentinelle Medical [Member]
Non-compete Agreements [Member]
|
Jun. 25, 2011
TCT International Co [Member]
Business Licenses [Member]
|
Jun. 25, 2011
TCT International Co [Member]
Trade Names [Member]
|
Jun. 25, 2011
Interlace Medical, Inc [Member]
Trade Names [Member]
|
Jun. 25, 2011
Sentinelle Medical [Member]
Trade Names [Member]
|
Dec. 25, 2010
Sentinelle Medical [Member]
In-process Research and Development [Member]
|
Jun. 01, 2011
TCT International Co [Member]
Purchase Price Allocation Adjustments [Member]
|
Jun. 25, 2011
TCT International Co [Member]
|
Jun. 01, 2011
TCT International Co [Member]
|
Jun. 25, 2011
Interlace Medical, Inc [Member]
|
Jun. 25, 2011
Interlace Medical, Inc [Member]
|
Jan. 06, 2011
Interlace Medical, Inc [Member]
|
Jul. 19, 2011
Beijing Healthcome Technology [Member]
|
Jun. 25, 2011
Sentinelle Medical [Member]
|
Dec. 25, 2010
Sentinelle Medical [Member]
|
Jun. 25, 2011
Sentinelle Medical [Member]
|
Sep. 25, 2010
Sentinelle Medical [Member]
|
Aug. 05, 2010
Sentinelle Medical [Member]
|
|
| Acquisition of equity interest, percentage | 100.00% | 100.00% | 100.00% | ||||||||||||||||||||||||
| Total purchase price | $ 141,936,000 | $ 141,900,000 | $ 213,398,000 | $ 213,398,000 | $ 114,251,000 | $ 114,251,000 | |||||||||||||||||||||
| Cash portion of purchase price | 135,000,000 | ||||||||||||||||||||||||||
| Cash | 100,000,000 | 126,798,000 | 126,798,000 | 126,800,000 | 9,800,000 | 84,751,000 | 84,751,000 | 84,800,000 | |||||||||||||||||||
| Estimated working capital adjustment | 6,900,000 | ||||||||||||||||||||||||||
| Deferred purchase price | 35,000,000 | ||||||||||||||||||||||||||
| Maximum additional contingent payment | 7,100,000 | 225,000,000 | 250,000,000 | ||||||||||||||||||||||||
| Cash flow projections discount rate related to contingent consideration | 15.00% | 16.00% | 10.00% | 17.00% | 12.70% | 12.70% | 15.60% | 16.50% | |||||||||||||||||||
| Contingent consideration arrangements recorded as compensation expense | 2,100,000 | 1,000,000 | 2,100,000 | ||||||||||||||||||||||||
| Contingent consideration obligation, fair value | 92,600,000 | 92,600,000 | 86,600,000 | 15,600,000 | 15,600,000 | 29,500,000 | |||||||||||||||||||||
| Contingent consideration fair value adjustments | (629,000) | 3,546,000 | 3,300,000 | 6,000,000 | 2,700,000 | 9,600,000 | |||||||||||||||||||||
| Maximum contingent earn-out payment | 200,000,000 | ||||||||||||||||||||||||||
| Payment of contingent consideration | 4,300,000 | ||||||||||||||||||||||||||
| Compensation expense ratably over the required service period | 2,114,000 | 2,114,000 | |||||||||||||||||||||||||
| General and administrative | $ 1,300,000 | $ 400,000 | $ 400,000 | $ 1,200,000 | |||||||||||||||||||||||
| Reevaluated discount rate in connection with determination of fair value of the contingent consideration liability | 17.00% | ||||||||||||||||||||||||||
| Finite-lived intangible assets, estimated useful life in years, minimum | 2 | 10 | |||||||||||||||||||||||||
| Finite-lived intangible assets, estimated useful life in years, maximum | 30 | 20 | |||||||||||||||||||||||||
| Finite-lived intangible assets, estimated useful life, years | 15 | 3 | 13 | ||||||||||||||||||||||||
| Finite-lived intangible assets, weighted average useful life, years | 19 | 13.6 | 10 | 13 | 9 | ||||||||||||||||||||||